Magnus Financial Group LLC purchased a new position in shares of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 2,311 shares of the financial services provider’s stock, valued at approximately $258,000.

Other institutional investors have also recently modified their holdings of the company. Parametric Portfolio Associates LLC lifted its stake in iShares Nasdaq Biotechnology ETF by 5.8% in the 1st quarter. Parametric Portfolio Associates LLC now owns 5,937 shares of the financial services provider’s stock valued at $664,000 after purchasing an additional 328 shares during the last quarter. First Trust Advisors LP increased its position in iShares Nasdaq Biotechnology ETF by 69.0% in the 1st quarter. First Trust Advisors LP now owns 16,417 shares of the financial services provider’s stock valued at $1,835,000 after acquiring an additional 6,701 shares during the period. Commerce Bank increased its position in iShares Nasdaq Biotechnology ETF by 1.5% in the 1st quarter. Commerce Bank now owns 710,753 shares of the financial services provider’s stock valued at $79,462,000 after acquiring an additional 10,414 shares during the period. Cambridge Investment Research Advisors Inc. increased its position in iShares Nasdaq Biotechnology ETF by 28.6% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 82,479 shares of the financial services provider’s stock valued at $9,221,000 after acquiring an additional 18,359 shares during the period. Finally, 1 North Wealth Services LLC increased its position in iShares Nasdaq Biotechnology ETF by 0.9% in the 1st quarter. 1 North Wealth Services LLC now owns 15,784 shares of the financial services provider’s stock valued at $1,765,000 after acquiring an additional 139 shares during the period. 69.34% of the stock is owned by institutional investors.

NASDAQ IBB traded up $0.43 on Friday, hitting $104.20. The company’s stock had a trading volume of 1,342,149 shares, compared to its average volume of 2,486,915. iShares Nasdaq Biotechnology ETF has a 1-year low of $89.01 and a 1-year high of $122.97.

TRADEMARK VIOLATION NOTICE: “2,311 Shares in iShares Nasdaq Biotechnology ETF (IBB) Purchased by Magnus Financial Group LLC” was reported by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this article can be read at https://www.watchlistnews.com/2311-shares-in-ishares-nasdaq-biotechnology-etf-ibb-purchased-by-magnus-financial-group-llc/3022053.html.

iShares Nasdaq Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Read More: What is the Consumer Price Index (CPI)?

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.